Novocure Hits Record Revenue and Raises 2026 Outlook

1. Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

The oncology sector continues to draw strong interest from life sciences investors as cancer cases rise and new treatment technologies advance. Novocure Ltd. (NVCR:NASDAQ) stands out in this environment through its proprietary Tumor Treating Fields approach that targets some of the most difficult cancers.

Why Novocure Stands Out in Oncology Today

Novocure has built a differentiated position by focusing on Tumor Treating Fields, a therapy that uses electric fields to disrupt cancer cell division. Novocure Ltd. (NVCR:NASDAQ) reported its strongest quarter yet in the three months ended June 30, 2026, with revenue reaching US$183.6 million, up 16 percent from the prior year, supported by 18 percent growth in active patients. This performance highlights the company's ability to expand adoption across multiple markets while improving operating efficiency.

Key Investor Takeaways

• Novocure delivered record quarterly revenue of US$183.6 million and raised full-year 2026 guidance to US$710-725 million.
• Optune Pax received CE Mark approval for pancreatic cancer, opening the first European launch in Germany.
• Active patients grew across all three marketed therapies, reaching 5,128 globally by June 30, 2026.
• Gross margin improved to 78 percent, aided by a one-time tariff refund, while adjusted EBITDA turned positive at US$10.8 million.
• An FDA decision on brain metastases treatment is expected in Q4 2026, representing a major potential catalyst.

Unique Business Model and Technology Platform

Novocure's model centers on Tumor Treating Fields therapy delivered through wearable devices. The approach is non-invasive and designed to work alongside standard treatments such as chemotherapy. Revenue comes from device rentals and related supplies, creating recurring income as patients remain on therapy. The company has expanded from its initial glioblastoma focus into pancreatic cancer, non-small cell lung cancer, and malignant pleural mesothelioma, broadening the addressable patient population.

Recent Catalysts Driving Growth

On July 23, 2026, the company announced financial results and operational updates that included several positive developments. Optune Pax received CE Mark approval for adult patients with locally advanced pancreatic cancer of exocrine origin when used with gemcitabine and nab-paclitaxel. Germany became the first European Union market for the launch. Active patients on Optune Pax reached 285 in the United States by quarter end, while Optune Lua patients grew 51 percent year-over-year to 207. Optune Gio, the core glioblastoma product, maintained steady growth with 4,636 active patients.

Industry Timing and Market Trends

Cancer incidence continues to climb globally. A March 26, 2026, article by Kinjel Shah for Yahoo Finance claimed that cancer incidences were rising, citing American Cancer Society projections of 2.1 million new cases and over 626,000 deaths in 2026. At the same time, treatment costs are rising. Keith Speights wrote an article for The Motley Fool discussing rising care costs, noting that U.S. cancer care spending could exceed US$245 billion by 2030. While some companies have reduced research spending, Novocure continues to invest, aligning with broader trends favoring innovative oncology therapies, as projected by IQVIA, which discussed the global pharma market projection for 2026.

 Views and Valuation Considerations

Analyst sentiment reflects both the growth potential and the need for further commercial proof. On July 13, 2026, Jessica Frye of JPMorgan Chase & Co. initiated coverage on the company with a Neutral rating and US$17 price target. On July 23, Wedbush reiterated Neutral while lifting its target to US$20. H.C. Wainwright & Co. maintained a Buy rating and raised its target to US$52, citing repeated guidance increases and commercial execution. Investor commentary from Chen Lin highlighted the stock's move above US$20 and potential upside to US$30-50 over time.

Share Structure and Upcoming Milestones

Novocure Ltd. has a market cap of US$2.32 billion and 115.82 million shares outstanding.

¹Institutions hold 86.68 percent, management and insiders own 9.95 percent, and retail investors hold the remaining 3.37 percent. The 52-week trading range stands at US$9.82 to US$20.55. Cash, cash equivalents, and short-term investments totaled US$440.6 million at quarter's end, providing a solid runway.

Key near-term events include an FDA premarket approval decision on TTFields for brain metastases in Q4 2026 and completion of enrollment in the Phase 3 KEYNOTE D58 trial for newly diagnosed glioblastoma patients.

Common Questions from Investors

Q: What are Tumor Treating Fields?

A: Tumor Treating Fields use low-intensity electric fields delivered through skin arrays to disrupt cancer cell division while sparing most healthy cells.

Q: What does CE Mark approval mean?

A: CE Mark certification allows a medical device to be sold in the European Economic Area once it meets applicable safety and performance standards.

Q: Why is the Q4 2026 FDA decision important?

A: A positive decision would expand approved uses into brain metastases, potentially adding a new revenue stream beyond the current glioblastoma franchise.

Q: How should investors view the raised guidance?

A: The increase to US$710-725 million in 2026 revenue signals sustained momentum across marketed products and improved visibility into commercial performance.

Novocure's combination of revenue growth, margin expansion, and pipeline progress positions the company for continued attention from investors monitoring the oncology space. Risks remain around adoption rates for newer indications and competition from other treatment modalities, so monitoring upcoming clinical and regulatory updates will be essential.